3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
NET
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Stomach Neoplasms
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Pancreatic Neoplasms
3
Lung Neoplasms
3
Carcinoma, Renal Cell
3
Recurrence
2
Neoplasm Metastasis
2
Melanoma
2
Kidney Neoplasms
2
Esophageal Neoplasms
2
Cholangiocarcinoma
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Urothelial Bladder Carcinoma
1
Urinary Bladder Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Solid Tumors
1
Solid Tumor
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Ovarian Neoplasms
1
Neoplasms
1
Multiple Myeloma
1
Metastatic Urothelial Cancer
1
Interventions
lutetium Lu 177 dotatate
6
Octreotide
3
pasireotide
2
lanreotide
2
gallium Ga 68 dotatate
2
copper dotatate CU-64
2
amino-acid, glucose, and electrolyte solution
2
Magnetic Resonance Spectroscopy
2
Lutetium-177
2
Lutetium
2
Ga(III)-DOTATOC
2
Everolimus
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
zimberelimab
1
irinotecan sucrosofate
1
abemaciclib
1
X-Rays
1
Temozolomide
1
Sunitinib
1
Receptor-Like Protein Tyrosine Phosphatases, Class 2
1
Radiosurgery
1
PM 01183
1
Oxaliplatin
1
Nivolumab
1
Leucovorin
1
Irinotecan
1
Ipilimumab
1
Folfox protocol
1
Fluorouracil
1
E-7386
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
zimberelimab
×
1 year
×
Clear all
NCT06790706
2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2
Recruiting
154 enrolled